Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Rises By 158.2%

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 150,000 shares, an increase of 158.2% from the August 30th total of 58,100 shares. Currently, 5.7% of the company’s shares are sold short. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is presently 0.2 days.

CAPR opened at $2.50 on Friday. Capricor Therapeutics has a 12 month low of $2.30 and a 12 month high of $11.50. The business has a fifty day moving average price of $2.81 and a 200 day moving average price of $2.34.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.21. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%. The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.22 million. As a group, research analysts forecast that Capricor Therapeutics will post -2.87 EPS for the current fiscal year.



Several equities research analysts have issued reports on CAPR shares. ValuEngine raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Friday. Zacks Investment Research cut Capricor Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, Maxim Group reissued a “hold” rating on shares of Capricor Therapeutics in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Capricor Therapeutics has an average rating of “Hold” and a consensus target price of $6.63.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More: Why does the United States have a lingering trade deficit?

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.